Multivariate analysis of transplant-related events
| Outcome . | HR (95% CI) . | P value . |
|---|---|---|
| OS | ||
| Age >60 vs <60 years | 2.27 (1.14-4.52) | .02 |
| Unrelated donor vs MRD | 1.93 (0.61-6.07) | .26 |
| Low-intermediate vs high-very-high-risk disease | 1.77 (0.81-3.83) | .15 |
| CsA + MMF or MTX vs CsA alone | 1.16 (0.38-3.51) | .79 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.60 (0.30-1.19) | .14 |
| GPFS | ||
| Unrelated donor vs MRD | 1.54 (0.87-2.75) | .14 |
| ATG vs no ATG | 0.92 (0.40-2.13) | .84 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.48 (0.27-0.85) | .01 |
| NRM | ||
| Unrelated donor vs MRD | 5.95 (0.75-47.35) | .09 |
| RIC vs MAC | 1.95 (0.67-5.70) | .22 |
| CsA + MMF or MTX vs CsA alone | 0.72 (0.12-4.21) | .72 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.87 (0.32-2.33) | .78 |
| Relapse progression | ||
| CMV donor/recipient negative vs others | 0.57 (0.25-1.31) | .19 |
| Low-intermediate vs high-very-high-risk disease | 2.59 (1.12-6.00) | .03 |
| ATG vs no ATG | 0.34 (0.12-0.94) | .04 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.75 (0.31-1.78) | .51 |
| Grade III-IV acute GVHD | ||
| Female donor to male recipient vs others | 0.38 (0.05-3.09) | .37 |
| Unrelated donor vs MRD | 2.21 (0.46-10.60) | .32 |
| ATG vs no ATG | 1.2 × 108 (0-∞) | 1.00 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.48 (0.13-1.60) | .22 |
| NIH grade 2-3 chronic GVHD | ||
| Low-intermediate vs high-very-high-risk disease | 8. 9 × 10−9 (0-∞) | .99 |
| ATG vs no ATG | 0.33 (0.09-1.23) | .10 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.03 (1.9 × 10−12-5.5 × 108) | .78 |
| Outcome . | HR (95% CI) . | P value . |
|---|---|---|
| OS | ||
| Age >60 vs <60 years | 2.27 (1.14-4.52) | .02 |
| Unrelated donor vs MRD | 1.93 (0.61-6.07) | .26 |
| Low-intermediate vs high-very-high-risk disease | 1.77 (0.81-3.83) | .15 |
| CsA + MMF or MTX vs CsA alone | 1.16 (0.38-3.51) | .79 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.60 (0.30-1.19) | .14 |
| GPFS | ||
| Unrelated donor vs MRD | 1.54 (0.87-2.75) | .14 |
| ATG vs no ATG | 0.92 (0.40-2.13) | .84 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.48 (0.27-0.85) | .01 |
| NRM | ||
| Unrelated donor vs MRD | 5.95 (0.75-47.35) | .09 |
| RIC vs MAC | 1.95 (0.67-5.70) | .22 |
| CsA + MMF or MTX vs CsA alone | 0.72 (0.12-4.21) | .72 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.87 (0.32-2.33) | .78 |
| Relapse progression | ||
| CMV donor/recipient negative vs others | 0.57 (0.25-1.31) | .19 |
| Low-intermediate vs high-very-high-risk disease | 2.59 (1.12-6.00) | .03 |
| ATG vs no ATG | 0.34 (0.12-0.94) | .04 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.75 (0.31-1.78) | .51 |
| Grade III-IV acute GVHD | ||
| Female donor to male recipient vs others | 0.38 (0.05-3.09) | .37 |
| Unrelated donor vs MRD | 2.21 (0.46-10.60) | .32 |
| ATG vs no ATG | 1.2 × 108 (0-∞) | 1.00 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.48 (0.13-1.60) | .22 |
| NIH grade 2-3 chronic GVHD | ||
| Low-intermediate vs high-very-high-risk disease | 8. 9 × 10−9 (0-∞) | .99 |
| ATG vs no ATG | 0.33 (0.09-1.23) | .10 |
| iNKT >0.11 × 106/kg vs <0.11 × 106/kg | 0.03 (1.9 × 10−12-5.5 × 108) | .78 |
Bold denotes statistically significant.